华仁药业参与京津冀“3+N”联盟部分西药和中成药带量联动接续采购中选

Core Viewpoint - Huarun Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement project (Project No: LH-YD2025-1) [1] - The Tianjin Pharmaceutical Procurement Center recently announced the selection results, confirming the company's products as winners in this procurement [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with a projected sales revenue of 823,200 yuan for 2024, accounting for 0.06% of the company's total revenue [1] - Betahistine hydrochloride sodium injection with a projected sales revenue of 2,220,300 yuan for 2024, accounting for 0.16% of the company's total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with a projected sales revenue of 9,995,400 yuan for 2024, accounting for 0.74% of the company's total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, representing 0.96% of the company's total revenue [1]